Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects
Hong-Jie Qian, Yu Wang, Meng-Qi Zhang, Yuan-Chao Xie, Qing-Qing Wu, Li-Yu Liang, Ye Cao, Hua-Qing Duan, Guang-Hui Tian, Juan Ma, Zhuo-Bing Zhang, Ning Li, Jing-Ying Jia, Jing Zhang, Haji Akber Aisa, Jing-Shan Shen, Chen Yu, Hua-Liang Jiang, Wen-Hong Zhang, Zhen Wang, Gang-Yi Liu
Acta Pharmacologica Sinica, doi:10.1038/s41401-022-00895-6
VV116 (JT001) is an oral drug candidate of nucleoside analog against SARS-CoV-2. The purpose of the three phase I studies was to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of VV116 in healthy subjects, as well as the effect of food on the pharmacokinetics and safety of VV116. Three studies were launched sequentially: Study 1 (single ascending-dose study, SAD), Study 2 (multiple ascending-dose study, MAD), and Study 3 (food-effect study, FE). A total of 86 healthy subjects were enrolled in the studies. VV116 tablets or placebo were administered per protocol requirements. Blood samples were collected at the scheduled time points for pharmacokinetic analysis. 116-N1, the metabolite of VV116, was detected in plasma and calculated for the PK parameters. In SAD, AUC and C max increased in an approximately dose-proportional manner in the dose range of 25-800 mg. T 1/2 was within 4.80-6.95 h. In MAD, the accumulation ratio for C max and AUC indicated a slight accumulation upon repeated dosing of VV116. In FE, the standard meal had no effect on C max and AUC of VV116. No serious adverse event occurred in the studies, and no subject withdrew from the studies due to adverse events. Thus, VV116 exhibited satisfactory safety and tolerability in healthy subjects, which supports the continued investigation of VV116 in patients with COVID-19.
AUTHOR CONTRIBUTIONS All authors contributed to the studies and manuscript. GYL, ZW, WHZ, HLJ, CY, JSS, HAA, JZ, JYJ, HJQ, HQD, and GHT designed and supervised the study; HJQ, GYL, CY, JYJ, QQW, MQZ and LYL performed and executed the study; YW, ZW, JM, YCX, ZBZ, and NL analyzed and interpreted the data; HJQ, QQW, LYL, YCX, and YC wrote the initial draft; all authors critically reviewed or revised the draft of the manuscript, and approved the final manuscript.
ADDITIONAL INFORMATION Competing interests: HQD and GHT are the employees of Vigonvita Life Science Co., Ltd, the sponsor of the study. JM, ZBZ, and NL are the employees of Shanghai Junshi Biosciences Co., Ltd., the parent company of the co-sponsor Shanghai JunTop Biosciences Co., Ltd. YCX, JSS, and HLJ filed a patent application on antiviral nucleoside analogs. The remaining authors declare no competing interests.
References
Agostini, Pruijssers, Chappell, Gribble, Lu et al., Smallmolecule antiviral β-d-N 4 -hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance, J Virol
Bernal, Da Silva, Musungaie, Kovalchuk, Gonzalez et al., Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, N Engl J Med
Du, Yang, Zhang, Neutralizing antibodies for the prevention and treatment of COVID-19, Cell Mol Immunol
Fischer, Eron, Holman, Cohen, Fang et al., A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus, Sci Transl Med
Grein, Ohmagari, Shin, Diaz, Asperges et al., Compassionate use of remdesivir for patients with severe Covid-19, N Engl J Med
Kaabi, Zhang, Xia, Yang, Qahtani et al., Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial, J Am Med Assoc
Li, Wang, Lavrijsen, Lamers, De Vries et al., SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination, Cell Res,
doi:10.1038/s41422-022-00618-wLi, Yang, Quan, Li, Advancement of prodrug approaches for nucleotide antiviral agents, Curr Top Med Chem
Olender, Perez, Go, Balani, Eg et al., Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care, Clin Infect Dis
Owen, Allerton, Anderson, Aschenbrenner, Avery et al., An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19, Science
Robson, Khan, Le, Paris, Demirbag et al., Coronavirus RNA proofreading: molecular basis and therapeutic targeting, Mol Cell
Rosenberg, Dorabawila, Easton, Bauer, Kumar et al., Covid-19 vaccine effectiveness in New York State, N Engl J Med
Seley-Radtke, Yates, The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part 1: early structural modifications to the nucleoside scaffold, Antivir Res
Spinello, Maria, Anna, Roberto, Gabriele, Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and non-ICU patients: clinical outcome and differences in posttreatment hospitalisation status, Pharmacol Res
Wang, Li, Dou, Shi, Duan et al., Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants, Emerg Microbes Infect
Xie, Yin, Zhang, Shang, Wang et al., Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2, Cell Res
Yates, Seley-Radtke, The evolution of antiviral nucleoside analogues: a review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold, Antivir Res
{ 'indexed': {'date-parts': [[2024, 1, 2]], 'date-time': '2024-01-02T20:43:09Z', 'timestamp': 1704228189820},
'reference-count': 19,
'publisher': 'Springer Science and Business Media LLC',
'issue': '12',
'license': [ { 'start': { 'date-parts': [[2022, 3, 16]],
'date-time': '2022-03-16T00:00:00Z',
'timestamp': 1647388800000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0'},
{ 'start': { 'date-parts': [[2022, 3, 16]],
'date-time': '2022-03-16T00:00:00Z',
'timestamp': 1647388800000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0'}],
'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2022, 12]]},
'abstract': '<jats:title>Abstract</jats:title><jats:p>VV116 (JT001) is an oral drug candidate of '
'nucleoside analog against SARS-CoV-2. The purpose of the three phase I studies was to '
'evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral '
'doses of VV116 in healthy subjects, as well as the effect of food on the pharmacokinetics and '
'safety of VV116. Three studies were launched sequentially: Study 1 (single ascending-dose '
'study, SAD), Study 2 (multiple ascending-dose study, MAD), and Study 3 (food-effect study, '
'FE). A total of 86 healthy subjects were enrolled in the studies. VV116 tablets or placebo '
'were administered per protocol requirements. Blood samples were collected at the scheduled '
'time points for pharmacokinetic analysis. 116-N1, the metabolite of VV116, was detected in '
'plasma and calculated for the PK parameters. In SAD, AUC and '
'<jats:italic>C</jats:italic><jats:sub>max</jats:sub> increased in an approximately '
'dose-proportional manner in the dose range of 25–800\u2009mg. '
'<jats:italic>T</jats:italic><jats:sub>1/2</jats:sub> was within 4.80–6.95\u2009h. In MAD, the '
'accumulation ratio for <jats:italic>C</jats:italic><jats:sub>max</jats:sub> and AUC indicated '
'a slight accumulation upon repeated dosing of VV116. In FE, the standard meal had no effect '
'on <jats:italic>C</jats:italic><jats:sub>max</jats:sub> and AUC of VV116. No serious adverse '
'event occurred in the studies, and no subject withdrew from the studies due to adverse '
'events. Thus, VV116 exhibited satisfactory safety and tolerability in healthy subjects, which '
'supports the continued investigation of VV116 in patients with COVID-19.</jats:p>',
'DOI': '10.1038/s41401-022-00895-6',
'type': 'journal-article',
'created': {'date-parts': [[2022, 3, 16]], 'date-time': '2022-03-16T10:05:53Z', 'timestamp': 1647425153000},
'page': '3130-3138',
'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy',
'source': 'Crossref',
'is-referenced-by-count': 33,
'title': 'Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against '
'SARS-CoV-2, in Chinese healthy subjects',
'prefix': '10.1038',
'volume': '43',
'author': [ {'given': 'Hong-jie', 'family': 'Qian', 'sequence': 'first', 'affiliation': []},
{'given': 'Yu', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Meng-qi', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Yuan-chao', 'family': 'Xie', 'sequence': 'additional', 'affiliation': []},
{'given': 'Qing-qing', 'family': 'Wu', 'sequence': 'additional', 'affiliation': []},
{'given': 'Li-yu', 'family': 'Liang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ye', 'family': 'Cao', 'sequence': 'additional', 'affiliation': []},
{'given': 'Hua-qing', 'family': 'Duan', 'sequence': 'additional', 'affiliation': []},
{'given': 'Guang-hui', 'family': 'Tian', 'sequence': 'additional', 'affiliation': []},
{'given': 'Juan', 'family': 'Ma', 'sequence': 'additional', 'affiliation': []},
{'given': 'Zhuo-bing', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ning', 'family': 'Li', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jing-ying', 'family': 'Jia', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jing', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Haji Akber', 'family': 'Aisa', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jing-shan', 'family': 'Shen', 'sequence': 'additional', 'affiliation': []},
{'given': 'Chen', 'family': 'Yu', 'sequence': 'additional', 'affiliation': []},
{'given': 'Hua-liang', 'family': 'Jiang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Wen-hong', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Zhen', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Gang-yi', 'family': 'Liu', 'sequence': 'additional', 'affiliation': []}],
'member': '297',
'published-online': {'date-parts': [[2022, 3, 16]]},
'reference': [ { 'key': '895_CR1',
'doi-asserted-by': 'publisher',
'first-page': 'e4166',
'DOI': '10.1093/cid/ciaa1041',
'volume': '73',
'author': 'SA Olender',
'year': '2021',
'unstructured': 'Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, et al. '
'Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a '
'cohort receiving standard of care. Clin Infect Dis. 2021;73:e4166–e74.',
'journal-title': 'Clin Infect Dis'},
{ 'key': '895_CR2',
'doi-asserted-by': 'publisher',
'first-page': '2293',
'DOI': '10.1038/s41423-021-00752-2',
'volume': '18',
'author': 'L Du',
'year': '2021',
'unstructured': 'Du L, Yang Y, Zhang X. Neutralizing antibodies for the prevention and '
'treatment of COVID-19. Cell Mol Immunol. 2021;18:2293–306.',
'journal-title': 'Cell Mol Immunol'},
{ 'key': '895_CR3',
'doi-asserted-by': 'publisher',
'first-page': '548',
'DOI': '10.1080/22221751.2022.2032374',
'volume': '11',
'author': 'F Wang',
'year': '2022',
'unstructured': 'Wang F, Li L, Dou Y, Shi R, Duan X, Liu H, et al. Etesevimab in '
'combination with JS026 neutralizing SARS-CoV-2 and its variants. Emerg '
'Microbes Infect. 2022;11:548–51.',
'journal-title': 'Emerg Microbes Infect'},
{ 'key': '895_CR4',
'doi-asserted-by': 'publisher',
'first-page': '35',
'DOI': '10.1001/jama.2021.8565',
'volume': '326',
'author': 'N Al Kaabi',
'year': '2021',
'unstructured': 'Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. '
'Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 '
'infection in adults: a randomized clinical trial. J Am Med Assoc. '
'2021;326:35–45.',
'journal-title': 'J Am Med Assoc.'},
{ 'key': '895_CR5',
'doi-asserted-by': 'publisher',
'first-page': '116',
'DOI': '10.1056/NEJMoa2116063',
'volume': '386',
'author': 'ES Rosenberg',
'year': '2022',
'unstructured': 'Rosenberg ES, Dorabawila V, Easton D, Bauer UE, Kumar J, Hoen R, et al. '
'Covid-19 vaccine effectiveness in New York State. N Engl J Med. '
'2022;386:116–27.',
'journal-title': 'N Engl J Med.'},
{ 'key': '895_CR6',
'doi-asserted-by': 'publisher',
'first-page': '1586',
'DOI': '10.1126/science.abl4784',
'volume': '374',
'author': 'DR Owen',
'year': '2021',
'unstructured': 'Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, '
'et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the '
'treatment of COVID-19. Science. 2021;374:1586–93.',
'journal-title': 'Science'},
{ 'key': '895_CR7',
'doi-asserted-by': 'publisher',
'unstructured': 'Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, et al. '
'SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, '
'nirmatrelvir, and the combination. Cell Res. 2022. '
'https://doi.org/10.1038/s41422-022-00618-w.',
'DOI': '10.1038/s41422-022-00618-w'},
{ 'key': '895_CR8',
'doi-asserted-by': 'publisher',
'first-page': 'eabl7430',
'DOI': '10.1126/scitranslmed.abl7430',
'volume': '14',
'author': 'WA Fischer',
'year': '2022',
'unstructured': 'Fischer WA, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. A '
'phase 2a clinical trial of molnupiravir in patients with COVID-19 shows '
'accelerated SARS-CoV-2 RNA clearance and elimination of infectious '
'virus. Sci Transl Med. 2022;14:eabl7430.',
'journal-title': 'Sci Transl Med'},
{ 'key': '895_CR9',
'doi-asserted-by': 'publisher',
'first-page': '509',
'DOI': '10.1056/NEJMoa2116044',
'volume': '386',
'author': 'A Jayk Bernal',
'year': '2022',
'unstructured': 'Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, '
'Delos Reyes V, et al. Molnupiravir for oral treatment of Covid-19 in '
'nonhospitalized patients. N Engl J Med. 2022;386:509–20.',
'journal-title': 'N Engl J Med.'},
{ 'key': '895_CR10',
'doi-asserted-by': 'publisher',
'first-page': '66',
'DOI': '10.1016/j.antiviral.2018.04.004',
'volume': '154',
'author': 'KL Seley-Radtke',
'year': '2018',
'unstructured': 'Seley-Radtke KL, Yates MK. The evolution of nucleoside analogue '
'antivirals: a review for chemists and non-chemists. Part 1: early '
'structural modifications to the nucleoside scaffold. Antivir Res. '
'2018;154:66–86.',
'journal-title': 'Antivir Res'},
{ 'key': '895_CR11',
'doi-asserted-by': 'publisher',
'first-page': '5',
'DOI': '10.1016/j.antiviral.2018.11.016',
'volume': '162',
'author': 'MK Yates',
'year': '2019',
'unstructured': 'Yates MK, Seley-Radtke KL. The evolution of antiviral nucleoside '
'analogues: a review for chemists and non-chemists. Part II: Complex '
'modifications to the nucleoside scaffold. Antivir Res. 2019;162:5–21.',
'journal-title': 'Antivir Res'},
{ 'key': '895_CR12',
'doi-asserted-by': 'publisher',
'first-page': '710',
'DOI': '10.1016/j.molcel.2020.07.027',
'volume': '79',
'author': 'F Robson',
'year': '2020',
'unstructured': 'Robson F, Khan KS, Le TK, Paris C, Demirbag S, Barfuss P, et al. '
'Coronavirus RNA proofreading: molecular basis and therapeutic targeting. '
'Mol Cell. 2020;79:710–27.',
'journal-title': 'Mol Cell'},
{ 'key': '895_CR13',
'doi-asserted-by': 'publisher',
'first-page': 'e01348',
'DOI': '10.1128/JVI.01348-19',
'volume': '93',
'author': 'ML Agostini',
'year': '2019',
'unstructured': 'Agostini ML, Pruijssers AJ, Chappell JD, Gribble J, Lu X, Andres EL, et '
'al. Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a '
'proofreading-intact coronavirus with a high genetic barrier to '
'resistance. J Virol. 2019;93:e01348–19.',
'journal-title': 'J Virol.'},
{ 'key': '895_CR14',
'doi-asserted-by': 'publisher',
'first-page': '1212',
'DOI': '10.1038/s41422-021-00570-1',
'volume': '31',
'author': 'Y Xie',
'year': '2021',
'unstructured': 'Xie Y, Yin W, Zhang Y, Shang W, Wang Z, Luan X, et al. Design and '
'development of an oral remdesivir derivative VV116 against SARS-CoV-2. '
'Cell Res. 2021;31:1212–4.',
'journal-title': 'Cell Res'},
{ 'key': '895_CR15',
'doi-asserted-by': 'publisher',
'first-page': '2909',
'DOI': '10.2174/1568026621666210728094019',
'volume': '21',
'author': 'Y Li',
'year': '2021',
'unstructured': 'Li Y, Yang B, Quan Y, Li Z. Advancement of prodrug approaches for '
'nucleotide antiviral agents. Curr Top Med Chem. 2021;21:2909–27.',
'journal-title': 'Curr Top Med Chem'},
{ 'key': '895_CR16',
'unstructured': 'Pharmaceuticals and Medical Devices Agency. Tokyo: Pharmaceuticals and '
'Medical Devices Agency; c2022. Gilead Sciences. Section 2.7-Clinical '
'Summary of Remdesivir Common Technical Document. 2020. p. 271. Available '
'from: '
'https://www.pmda.go.jp/drugs/2020/P20200518003/230867000_30200AMX00455_K100_1.pdf. '
'Accessed 16 Feb 2022.'},
{ 'key': '895_CR17',
'doi-asserted-by': 'crossref',
'unstructured': 'Spinello A, Maria VC, Anna LR, Roberto R, Cecilia B, Gabriele P, et al. '
'Compassionate remdesivir treatment of severe Covid-19 pneumonia in '
'intensive care unit (ICU) and non-ICU patients: clinical outcome and '
'differences in post-treatment hospitalisation status. Pharmacol Res. '
'2020;158:104899.',
'DOI': '10.1016/j.phrs.2020.104899'},
{ 'key': '895_CR18',
'doi-asserted-by': 'crossref',
'unstructured': 'Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Catagna A, et al. '
'Compassionate use of remdesivir for patients with severe Covid-19. N '
'Engl J Med. 2020;382:2327–36.',
'DOI': '10.1056/NEJMc2015312'},
{ 'key': '895_CR19',
'unstructured': 'Pharmaceuticals and Medical Devices Agency. Tokyo: Pharmaceuticals and '
'Medical Devices Agency; c2022. Gilead Sciences. Section 2.6.4 '
'Pharmacokinetics Written Summary of Remdesivir Common Technical '
'Document. 2020. p. 127. Available from: '
'https://www.pmda.go.jp/drugs/2020/P20200518003/230867000_30200AMX00455_I100_1.pdf. '
'Accessed 16 Feb 2022.'}],
'container-title': 'Acta Pharmacologica Sinica',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.nature.com/articles/s41401-022-00895-6.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://www.nature.com/articles/s41401-022-00895-6',
'content-type': 'text/html',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://www.nature.com/articles/s41401-022-00895-6.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 11, 30]],
'date-time': '2022-11-30T10:09:03Z',
'timestamp': 1669802943000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.nature.com/articles/s41401-022-00895-6'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 3, 16]]},
'references-count': 19,
'journal-issue': {'issue': '12', 'published-print': {'date-parts': [[2022, 12]]}},
'alternative-id': ['895'],
'URL': 'http://dx.doi.org/10.1038/s41401-022-00895-6',
'relation': {},
'ISSN': ['1671-4083', '1745-7254'],
'subject': ['Pharmacology (medical)', 'Pharmacology', 'General Medicine'],
'container-title-short': 'Acta Pharmacol Sin',
'published': {'date-parts': [[2022, 3, 16]]},
'assertion': [ { 'value': '18 February 2022',
'order': 1,
'name': 'received',
'label': 'Received',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': '3 March 2022',
'order': 2,
'name': 'accepted',
'label': 'Accepted',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': '16 March 2022',
'order': 3,
'name': 'first_online',
'label': 'First Online',
'group': {'name': 'ArticleHistory', 'label': 'Article History'}},
{ 'value': 'HQD and GHT are the employees of Vigonvita Life Science Co., Ltd, the sponsor '
'of the study. JM, ZBZ, and NL are the employees of Shanghai Junshi Biosciences '
'Co., Ltd., the parent company of the co-sponsor Shanghai JunTop Biosciences '
'Co., Ltd. YCX, JSS, and HLJ filed a patent application on antiviral nucleoside '
'analogs. The remaining authors declare no competing interests.',
'order': 1,
'name': 'Ethics',
'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}]}
